Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE
Dan Li, Bharati Matta, Su Song, Victoria Nelson, Kirsten Diggins, Kim R. Simpfendorfer, Peter K. Gregersen, Peter Linsley, Betsy J. Barnes
Dan Li, Bharati Matta, Su Song, Victoria Nelson, Kirsten Diggins, Kim R. Simpfendorfer, Peter K. Gregersen, Peter Linsley, Betsy J. Barnes
View: Text | PDF
Research Article Genetics Immunology

IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE

  • Text
  • PDF
Abstract

Genetic variants within or near the interferon regulatory factor 5 (IRF5) locus associate with systemic lupus erythematosus (SLE) across ancestral groups. The major IRF5-SLE risk haplotype is common across populations, yet immune functions for the risk haplotype are undefined. We characterized the global immune phenotype of healthy donors homozygous for the major risk and nonrisk haplotypes and identified cell lineage–specific alterations that mimic presymptomatic SLE. Contrary to previous studies in B lymphoblastoid cell lines and SLE immune cells, IRF5 genetic variants had little effect on IRF5 protein levels in healthy donors. Instead, we detected basal IRF5 hyperactivation in the myeloid compartment of risk donors that drives the SLE immune phenotype. Risk donors were anti-nuclear antibody positive with anti-Ro and -MPO specificity, had increased circulating plasma cells and plasmacytoid dendritic cells, and had enhanced spontaneous NETosis. The IRF5-SLE immune phenotype was conserved over time and probed mechanistically by ex vivo coculture, indicating that risk neutrophils are drivers of the global immune phenotype. RNA-Seq of risk neutrophils revealed increased IRF5 transcript expression, IFN pathway enrichment, and decreased expression of ROS pathway genes. Altogether, the data support that individuals carrying the IRF5-SLE risk haplotype are more susceptible to environmental/stochastic influences that trigger chronic immune activation, predisposing to the development of clinical SLE.

Authors

Dan Li, Bharati Matta, Su Song, Victoria Nelson, Kirsten Diggins, Kim R. Simpfendorfer, Peter K. Gregersen, Peter Linsley, Betsy J. Barnes

×

Figure 7

Ex vivo coculture of risk NETs with nonrisk PBMCs replicates the IRF5 risk immune phenotype.

Options: View larger image (or click on image) Download as PowerPoint
Ex vivo coculture of risk NETs with nonrisk PBMCs replicates the IRF5 ri...
(A–G) Similar to Figure 6, neutrophils from nonrisk (NR-N) and risk donors (R-N) were plated and cocultured with nonrisk PBMCs (NR-P). PBMCs were harvested at the 3 time points for analysis. (A) Cells were harvested after 4 hours’ coculture to examine IRF5 activation in pDCs by imaging flow cytometry (1-way ANOVA with Tukey’s multiple-comparisons test; n = 11 risk and nonrisk donors). (B) Cells were harvested after overnight coculture to examine pDC numbers (B and C) and activation via CD40 surface expression by flow cytometry (D and E) (1-way ANOVA with Tukey’s multiple-comparisons test; n = 12 risk and nonrisk donors). B is pregated on CD45+ cells and D on CD45+CD123+BDCA2+ cells. (F) Cells were harvested after 7 days of coculture to examine PB differentiation by flow cytometry. Representative dot plots (F) and summarized data (G) are shown (unpaired 2-tailed t test; n = 13 risk and nonrisk donors). Experiments were repeated 3 times (A–G). Single data points represent cells from individual donors. Data are presented as mean ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts